HD-OPM Archive
Topics › Inflammation & CRP

Peter Libby on inflammation in atherosclerosis, clonal hematopoiesis and colchicine

Louis Nervegna · Jun 20, 2025 · ♥ 3 reactions · 0 comments · original Facebook post
Inflammation & CRPCardiovascular disease: the big picture
↻ This is a repost. The main version (highest ranked) is Peter Libby on inflammation in atherosclerosis, CHIP, canakinumab and colchicine · Feb 17, 2024.
AI summary & key facts

A video of Peter Libby discussing atherosclerosis as a disease of constant cellular struggle in plaques, the role of superficial erosion, and how bone marrow signaling and clonal hematopoiesis drive leukocyte accumulation. He covers anti-inflammatory therapies such as canakinumab and colchicine that have shown cardiovascular benefit.

#inflammationHD #colchicineHD #crpHD #il6HD #peterlibbyHD #brighamwomensHD #harvardHD #chipHD #canakinumabHD

Research cited

Shared from Gokhan Can · original post

This video covers a discussion with Dr. Peter Libby about the role of inflammation in atherosclerosis, highlighting it as a disease characterized by constant cellular struggle within plaques and an increasingly recognized contribution of superficial erosion to thrombotic complications. Dr. Libby explains how bone marrow inflammatory signaling and clonal hematopoiesis drive leukocyte accumulation in plaques, and discusses anti-inflammatory therapies like canakinumab and colchicine which have demonstrated cardiovascular benefits, underscoring inflammation as a promising therapeutic target. As research provides deeper insights into inflammatory pathways, it will enable more precise anti-inflammatory interventions to improve outcomes in atherosclerosis.

← newer: Inflammation is a causal risk factor; CRP predicts heart disolder: Libby vs Raal debate: residual inflammatory risk versus LDL →